Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c(+) Expression in Tumor

INTRODUCTION: Mesothelin (MSLN) is overexpressed in several tumors including ovarian cancer and is the target of current trials. There is limited and conflicting data on MSLN prognostic impact in ovarian cancer. METHODS: We performed a retrospective study on patients with high-grade serous ovarian c...

Descripción completa

Detalles Bibliográficos
Autores principales: Magalhaes, Isabelle, Fernebro, Josefin, Abd Own, Sulaf, Glaessgen, Daria, Corvigno, Sara, Remberger, Mats, Mattsson, Jonas, Dahlstrand, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595982/
https://www.ncbi.nlm.nih.gov/pubmed/33052561
http://dx.doi.org/10.1007/s12325-020-01520-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595982/
https://www.ncbi.nlm.nih.gov/pubmed/33052561
http://dx.doi.org/10.1007/s12325-020-01520-w

Ejemplares similares